Who
Ray Kurzweil
Director
Company insider
Files Form 4 as: Director, United Therapeutics; Director, Inforte.
In numbers
- Trades disclosed
- 155
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $22.3M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 24 Feb 2006
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,190 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,190 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $500K4,910 at $101.80 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.4M4,910 at $489.02 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,910 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,910 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $500K4,910 at $101.80 | filing |
| 4 Mar 2026filed 5 Mar 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.4M4,910 at $489.02 | filing |
| 25 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —590 at $0.00 | filing |
| 25 Jul 2025filed 28 Jul 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —590 at $0.00 | filing |
| 24 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650 at $0.00 | filing |
| 24 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,830 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $2.6M15,000 at $175.43 | filing |
News
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $725.00UTHR · dailypolitical.com · 22 Oct 2026Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under planUTHR · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Ray Kurzweil; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.